Form 4: Arvinas Inc. Executive Noah Berkowitz Reports Stock and Option Awards

Chief Medical Officer Noah Berkowitz reports the acquisition of restricted stock units and stock options in Arvinas, Inc.

Summary

• Noah Berkowitz, Chief Medical Officer of Arvinas, Inc., filed a Form 4 on May 13, 2025.
• The report details the grant of 59,600 restricted stock units (RSUs) and 91,000 stock options on May 9, 2025.
• The RSUs and options were granted under the company's 2018 Stock Incentive Plan.
• The RSUs represent a contingent right to receive one share of Arvinas' common stock upon settlement for no consideration.
• The RSUs and options vest over two years, with 1/2 vesting on May 9, 2026, and the remainder on May 9, 2027, contingent upon continued service with the Issuer.
• Following the reported transactions, Berkowitz beneficially owns 169,623 shares of common stock and 91,000 stock options.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard executive compensation practices, indicating confidence in the company's future.

Positives

• The grant of RSUs and stock options to the Chief Medical Officer aligns his interests with those of the shareholders.
• The vesting schedule incentivizes continued service and commitment to the company's long-term success.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule of the RSUs and options suggests an expectation of continued service from the executive.

Industry Context

Stock option and RSU grants are common compensation practices in the biotechnology industry to attract and retain key executives.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry, often used by companies like Amgen, Gilead, and Biogen.
• The vesting schedule of two years is relatively standard, aligning with typical retention incentives.
• The size of the grant is likely benchmarked against peer companies of similar market capitalization and stage of development.

Stakeholder Impact

• The stock and option grants could have a dilutive effect on existing shareholders.
• The grants incentivize the executive to work towards increasing shareholder value.

Key Dates

Keywords

Form 4, Arvinas, Berkowitz, Stock Options, Restricted Stock Units, ARVN, Beneficial Ownership, Chief Medical Officer